Pre-surgical metformin In uterine malignancy (PREMIUM): a multi-center, randomized double-blind, placebo-controlled phase 3 trial
Slade, Richard J
AffiliationDivision of Cancer Sciences, University of Manchester
MetadataShow full item record
AbstractPurpose Endometrioid endometrial cancer is strongly associated with obesity and insulin resistance. Metformin, an insulin sensitizer, reduces endometrial tumor growth in vitro. Pre-surgical window studies allow rapid in vivo assessment of anti-tumor activity. Previous window studies found metformin reduced endometrial cancer proliferation but these lacked methodological rigor. PREMIUM measured the anti-proliferative effect of metformin in vivo using a robust window study design. PATIENTS AND METHODS: A multicenter, double-blind, placebo-controlled trial randomized women with atypical hyperplasia or endometrioid endometrial cancer to receive metformin (850mg daily for three days, and twice daily thereafter) or placebo for 1-5 weeks until surgery. The primary outcome was post-treatment immunohistochemical expression of Ki-67. Secondary outcomes investigated the effect of metformin on markers of the PI3K-Akt-mTOR and insulin signaling pathways and obesity. RESULTS: Eighty-eight women received metformin (n=45) or placebo (n=43) and completed treatment. There was no overall difference in post-treatment Ki-67 between the metformin and placebo arms, in an ANCOVA analysis adjusting for baseline Ki-67 expression (mean difference -0.57%, 95% CI -7.57%, 6.42%, p=0.87). Metformin did not affect expression of markers of the PI3K-Akt-mTOR or insulin signaling pathways, and did not result in weight loss. CONCLUSIONS: Short-term treatment with standard diabetic doses of metformin does not reduce tumor proliferation in women with endometrioid endometrial cancer awaiting hysterectomy. This study does not support a biological effect of metformin in endometrial cancer and casts doubt on its potential application in the primary and adjuvant treatment settings.
CitationKitson S, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, et al. Pre-surgical metformin In uterine malignancy (PREMIUM): a multi-center, randomized double-blind, placebo-controlled phase 3 trial. Clin Cancer Res. 2018 Dec 18.
JournalClincal Cancer Research
- Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
- Authors: Sivalingam VN, Kitson S, McVey R, Roberts C, Pemberton P, Gilmour K, Ali S, Renehan AG, Kitchener HC, Crosbie EJ
- Issue date: 2016 Feb 2
- Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
- Authors: Soliman PT, Zhang Q, Broaddus RR, Westin SN, Iglesias D, Munsell MF, Schmandt R, Yates M, Ramondetta L, Lu KH
- Issue date: 2016 Dec
- Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
- Authors: Schuler KM, Rambally BS, DiFurio MJ, Sampey BP, Gehrig PA, Makowski L, Bae-Jump VL
- Issue date: 2015 Feb
- Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.
- Authors: Zhao Y, Sun H, Feng M, Zhao J, Zhao X, Wan Q, Cai D
- Issue date: 2018 May
- Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial.
- Authors: Petchsila K, Prueksaritanond N, Insin P, Yanaranop M, Chotikawichean N
- Issue date: 2020 Mar 1